Isavuconazole for the Treatment of Cerebral Aspergillosis: A Retrospective European EFISG Study

Isavuconazole for the Treatment of Cerebral Aspergillosis: A Retrospective European EFISG Study

2024.09.17
Cerebral aspergillosis (CA) is a lethal invasive fungal infection, with current national and international guidelines recommending voriconazole as the first-line antifungal treatment. While newer triazoles, such as isavuconazole, demonstrate good blood-brain barrier penetration, there is still limited clinical evidence to confirm their efficacy and safety for treating CA. Recently, Clinical Infectious Diseases published a retrospective study led by the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). The study highlights that isavuconazole is well-tolerated in the treatment of CA, with mortality rates comparable to those of voriconazole.
Dr. Jianxiang Wang: Leading Research, Continuous Innovation! Focusing on the Practice and Vision of CAR-T Cell Therapy in China

Dr. Jianxiang Wang: Leading Research, Continuous Innovation! Focusing on the Practice and Vision of CAR-T Cell Therapy in China

2024.09.17
In early September 2024, the 5th Tianjin International Lymphoma Conference was held from September 6 to 8, amid the golden season of autumn. This conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, creating a high-end academic platform for international exchange and collaboration. During the event, Hematology Frontier invited Dr. Jianxiang Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College to provide an in-depth analysis of the current state and future trends of CAR-T cell therapy in China from his academic perspective.
Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference

Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference

2024.09.17
From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for international academic exchange and cooperation. During the event, Hematology Frontier invited Dr. Wei Sang from The Affiliated Hospital of Xuzhou Medical University to provide an in-depth analysis of CAR-T cell therapy in different hematologic malignancies and explore strategies for optimizing treatment outcomes.
Expert Insights from the 2024 ESMO Congress l The INSPIRE Study Shines on the International Stage Once Again

Expert Insights from the 2024 ESMO Congress l The INSPIRE Study Shines on the International Stage Once Again

2024.09.17
The European Society for Medical Oncology Congress 2024(ESMO 2024) opened on September 13, in Barcelona,Spain. Lung cancer remains one of the key areas of focus,with several groundbreaking studies presented at the conference. Oncology Frontier invited Dr.Yuankai Shi, principal investigator of the INSPIRE study from the Cancer Hospital Chinese Academy of Medical Sciences,to share the latest data from this year's ESMO conference and discuss the clinical value of the study in treating anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer(NSCLC).
Gut丨MED12 Loss Activates Retrotransposons to Enhance Immunotherapy Sensitivity in Pancreatic Cancer

Gut丨MED12 Loss Activates Retrotransposons to Enhance Immunotherapy Sensitivity in Pancreatic Cancer

2024.09.15
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by high mortality rates and limited treatment options. Immunotherapy, particularly immune checkpoint blockade (ICB), has shown remarkable efficacy in treating cancers like melanoma and non-small cell lung cancer. However, many PDAC patients exhibit poor responses to ICB, mainly due to the tumor’s low immunogenicity and its immunosuppressive tumor microenvironment (TME). Inhibiting epigenetic regulators, such as SETDB1, KDM5B, and PHF8, has been shown to induce retrotransposon-mediated immune responses, thereby enhancing sensitivity to immunotherapy. While this approach shows promise in cancer treatment, its role in PDAC remains unclear. A recent study published in Gut identifies the key role of MED12 in modulating TME through the epigenetic silencing of retrotransposons, thus reshaping the immune TME in PDAC.
Wetland Virus: Chinese Scientists Discover a New Tick-Borne Virus

Wetland Virus: Chinese Scientists Discover a New Tick-Borne Virus

2024.09.15
On September 4, a team of Chinese researchers led by Dr. Wei Liu and Dr. Hao Li from the State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, along with Ningyi Jin’s team from the Changchun Institute of Veterinary Medicine, published a groundbreaking study in the New England Journal of Medicine (NEJM). The report details the discovery of a new tick-borne RNA virus, named the Wetland Virus (WELV), found in a wetland park in Nei Mongol. This discovery enhances our understanding of tick-borne diseases and provides new insights into the research and prevention of emerging infectious diseases globally.
SOHO 2024丨Dr. Peihua Lu: CD7 CAR-T Cell Therapy Opens New Pathways to Cure, Reshaping the Future of T-Cell Malignancy Treatment

SOHO 2024丨Dr. Peihua Lu: CD7 CAR-T Cell Therapy Opens New Pathways to Cure, Reshaping the Future of T-Cell Malignancy Treatment

2024.09.15
The 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4 to 7, 2024. It brought together leading experts in hematologic oncology from around the world to discuss the latest research findings and explore new treatment strategies. Among the numerous topics discussed, the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) was a focal point due to the high relapse rate and treatment complexity associated with these diseases. Traditional treatments often fail to provide long-term remission, and CAR-T cell therapy faces the challenge of inadvertently targeting healthy T-cells, further complicating treatment.
Dr. Hongmei Jing: A New Era of Precision Medicine in Lymphoma Treatment

Dr. Hongmei Jing: A New Era of Precision Medicine in Lymphoma Treatment

2024.09.15
With the rapid advancements in medical technology and deeper insights into the mechanisms of lymphoma, traditional chemotherapy is gradually giving way to a new era of precision-targeted and immunotherapies. Innovative drugs are emerging like bamboo shoots after the rain, offering personalized treatment paths tailored to lymphoma patients. This marks the dawn of a new era in disease management, with the promise of more effective and optimistic treatment outcomes. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Hongmei Jing from Peking University Third Hospital to provide a comprehensive analysis of the current state of lymphoma treatment in China, explore future research directions, and discuss the field's ongoing development.
EBMT China’s Voice | Professors Xiaoyan Ke and Kai Hu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients

EBMT China’s Voice | Professors Xiaoyan Ke and Kai Hu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients

2024.09.15
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Xiaoyan Ke from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Kai Hu from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.